Ghatnekar, O., Hjalte, F., & Taylor, M. (2010). Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib – a Swedish model application. Acta Oncologica, 49(6), 851–858. https://doi.org/10.3109/0284186X.2010.495132